Purpose: The ORIGIN trial showed that daily supplementation with 1 g of n–3 fatty acids did not reduce the rate of Cardiovascular (CV) events in high risk patients with type 2 Diabetes Mellitus (DM) or IFG/IGT. This ancillary analysis of the trial is aimed to evaluate the effect of this treatment in the subgroup of patients with a recent Myocardial Infarction (MI) in whom the use of n–3 fatty acids has been previously demonstrated to be able to prevent CV events in patients within 3 months of a MI.
Methods: The ORIGIN study randomly assigned patients to receive a 1g capsule containing at least 900 mg (90% or more) of ethyl esters of n–3 fatty acids or placebo daily. Long term outcomes were compared between n–3 fatty acids and placebo in the subgroup of patients with a recent MI (<6 months). Estimates of the hazard ratios and two-sided 95% confidence intervals were calculated with the use of a Cox regression model stratified according to study treatments, baseline metabolic status and a history of CV disease.
Results: Of the 12,536 patients entered in ORIGIN, 931 suffered a MI in the 6 months prior to randomization. Mean age was 62 years, female gender accounted for 23% of the cases. The incidences of the primary outcome of the study (CV death) and of other relevant CV event during a median follow-up period of 6.2 years are reported in the Table.
Conclusions: As in the overall population of the study of high risk patients with a recent diagnosis of DM or IGT/IGF, a daily supplementation with 1 g of n–3 fatty acids did not reduce the rate of CV events even in those with a recent MI.